Search clinical trials for: beta-II-agonist, inhale steroid
Total 4778 results
-
Forest LaboratoriesMylan LaboratoriesTerminated
-
Mylan Bertek PharmaceuticalsCompletedHypertensionUnited States
-
University of California, San DiegoRecruiting
-
Ain Shams UniversityRecruiting
-
National Taiwan University HospitalCompletedRecurrence of Overactive Bladder SyndromeTaiwan
-
Astellas Pharma IncCompleted
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Imperial College LondonFoundation for Circulatory HealthCompleted
-
University of MiamiForest LaboratoriesCompleted
-
Emory UniversityGeorgia Institute of TechnologyCompletedAtherosclerosis | Endothelial FunctionUnited States
-
Astellas Pharma IncCompletedHealthy Subjects | Pharmacokinetics of MirabegronNetherlands
-
Daniel Burdick, MDAstellas Pharma US, Inc.Completed
-
HealthPartners InstituteCompletedOveractive Bladder | Parkinson Disease | Impaired CognitionUnited States
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of MirabegronUnited States
-
Icahn School of Medicine at Mount SinaiForest LaboratoriesCompletedHypertension | Left Ventricular Diastolic DysfunctionUnited States
-
McMaster UniversityCompleted
-
Medical University of ViennaRoche Pharma AGCompletedCoronary Artery Disease | Heart Failure | Diabetes MellitusAustria
-
Samsung Medical CenterCompleted
-
Jack RubinsteinForest LaboratoriesTerminated
-
Mylan Bertek PharmaceuticalsCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveGermany
-
Astellas Pharma Europe B.V.CompletedNeurogenic Detrusor OveractivityBelgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
-
Minneapolis Heart Institute FoundationForest LaboratoriesTerminatedCoronary Artery DiseaseUnited States
-
Velicept Therapeutics, Inc.CompletedHealthy Subjects, Overactive Bladder
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedHealthy Subjects | Pharmacokinetics of YM178United States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
University of CalgaryChildren's Hospital of Eastern OntarioWithdrawn
-
Astellas Pharma Global Development, Inc.RecruitingNeurogenic Detrusor OveractivityPhilippines, Turkey, Belgium, Denmark
-
Tianjin Medical University General HospitalRecruiting
-
Mylan Bertek PharmaceuticalsCompletedHypertensionUnited States
-
Oslo University HospitalMills DACompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Canada
-
Astellas Pharma Global Development, Inc.TerminatedPharmacokinetics of Mirabegron | Overactive Bladder (OAB)Korea, Republic of, Russian Federation, Turkey
-
Forest LaboratoriesCompletedHypertensionUnited States
-
University Hospitals Cleveland Medical CenterWithdrawnOveractive BladderUnited States
-
Astellas Pharma Europe B.V.CompletedOveractive Bladder | Neurogenic Detrusor OveractivityDenmark, Poland
-
Astellas Pharma IncCompletedHealthy Subjects | Bioavailability | Pharmacokinetics of MirabegronNetherlands
-
Forest LaboratoriesCompletedHypertensionUnited States
-
Women and Infants Hospital of Rhode IslandPatient-Centered Outcomes Research Institute; University of California, San... and other collaboratorsRecruitingUrgency Urinary IncontinenceUnited States
-
Mayo ClinicForest LaboratoriesTerminatedHypertensionUnited States
-
University of Mississippi Medical CenterTerminated
-
Berlin-Chemie AG Menarini GroupCompletedHypertensionEstonia
-
Mylan Bertek PharmaceuticalsCompleted
-
Seoul National University HospitalUnknownOveractive Bladder | Parkinson DiseaseKorea, Republic of
-
AstraZenecaCompleted
-
Weill Medical College of Cornell UniversityForest LaboratoriesCompletedHypertensionUnited States
-
University of FloridaForest LaboratoriesCompletedHypertensionUnited States
-
Emory UniversityForest LaboratoriesCompleted